Literature DB >> 26055039

Impact of tonsillectomy combined with steroid pulse therapy on immunoglobulin A nephropathy depending on histological classification: a multicenter study.

Tetsu Miyamoto1, Tomoya Nishino2, Takashi Nakata3, Yuji Sato4, Hiroyuki Komatsu5, Tadashi Uramatsu2, Nana Ishimatsu6, Kaede Ishida3, Ryota Serino7, Yutaka Otsuji6, Masanobu Miyazaki8, Tadashi Tomo9, Masahito Tamura7, Shouichi Fujimoto10.   

Abstract

BACKGROUND: In addition to corticosteroids and inhibition of the renin-angiotensin-aldosterone system, tonsillectomy with steroid pulse therapy (TSP) may have a beneficial impact on the clinical course of IgA nephropathy (IgAN). However, there is still much uncertainty regarding the indications for therapy, treatment protocol, and therapeutic options for IgAN.
METHODS: In this multicenter retrospective cohort study, we enrolled 284 patients with biopsy-proven IgAN who received TSP or corticosteroid therapy or conservative therapy. The effects of TSP on clinical remission (CR) were evaluated after a median follow-up period of 4.1 years in relation to histological classifications.
RESULTS: Among the 284 participants, 161 patients received TSP. During the observation time, 141 patients (49.6%) achieved CR, with a median time to remission of 397 days. In multivariate Cox regression analyses, TSP had an impact on achieving CR in only the group with histological grade 3 defined as glomerulosclerosis, crescent formation or adhesion to Bowman's capsule in 10-30% of all biopsied glomeruli, or mild cellular infiltration in the interstitium (hazard ratio (HR) 4.29, 95% confidence interval (95%CI) 1.88-11.19, P < 0.001). TSP independently contributed to a higher incidence of CR, particularly in the patient group showing evident mesangial hypercellularity (HR 2.54, 95%CI 1.38-5.08, P = 0.002).
CONCLUSIONS: TSP may have a beneficial effect on the clinical course in IgAN patients with mild to moderate glomerular and interstitial lesions, particularly with distinct mesangial cell proliferation.

Entities:  

Keywords:  IgA nephropathy; Pathological classification; Tonsillectomy

Mesh:

Substances:

Year:  2015        PMID: 26055039     DOI: 10.1007/s10157-015-1131-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  26 in total

1.  Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.

Authors:  O Hotta; M Miyazaki; T Furuta; S Tomioka; S Chiba; I Horigome; K Abe; Y Taguma
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

2.  Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.

Authors:  Philip Kam-Tao Li; Chi Bon Leung; Kai Ming Chow; Yuk Lun Cheng; Samuel Ka-Shun Fung; Siu Ka Mak; Anthony Wing-Chung Tang; Teresa Yuk-Hwa Wong; Chun Yu Yung; Jonathan Chee-Unn Yung; Alex Wai-Yin Yu; Cheuk Chun Szeto
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

3.  Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy.

Authors:  Isseki Maeda; Tomoshige Hayashi; Kyoko Kogawa Sato; Mikiko Okumoto Shibata; Masahiro Hamada; Masatsugu Kishida; Chizuko Kitabayashi; Takashi Morikawa; Noriyuki Okada; Michiaki Okumura; Masayo Konishi; Yoshio Konishi; Ginji Endo; Masahito Imanishi
Journal:  Nephrol Dial Transplant       Date:  2012-04-05       Impact factor: 5.992

4.  Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathy.

Authors:  Ayami Ochi; Takahito Moriyama; Takashi Takei; Keiko Uchida; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2012-07-26       Impact factor: 2.370

5.  Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy.

Authors:  Yuko Shima; Koichi Nakanishi; Taketsugu Hama; Masashi Sato; Hironobu Mukaiyama; Hiroko Togawa; Ryojiro Tanaka; Hiroshi Kaito; Kandai Nozu; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2014-06-07       Impact factor: 3.714

Review 6.  Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy?

Authors:  Ladan Zand; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2014-04-10       Impact factor: 5.992

7.  Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy.

Authors:  Yukihiko Kawasaki; Kei Takano; Kazuhide Suyama; Masato Isome; Hideki Suzuki; Hiroko Sakuma; Tomoo Fujiki; Hitoshi Suzuki; Mitsuaki Hosoya
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

Review 8.  Risk stratification of patients with IgA nephropathy.

Authors:  Sean J Barbour; Heather N Reich
Journal:  Am J Kidney Dis       Date:  2012-04-11       Impact factor: 8.860

9.  A multicenter prospective cohort study of tonsillectomy and steroid therapy in Japanese patients with IgA nephropathy: a 5-year report.

Authors:  Mariko Miyazaki; Osamu Hotta; Atsushi Komatsuda; Shigeru Nakai; Tatsuya Shoji; Chikao Yasunaga; Yoshio Taguma
Journal:  Contrib Nephrol       Date:  2007       Impact factor: 1.580

10.  IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.

Authors:  Rosanna Coppo; Licia Peruzzi; Alessandro Amore; Antonio Piccoli; Pierre Cochat; Rosario Stone; Martin Kirschstein; Tommy Linné
Journal:  J Am Soc Nephrol       Date:  2007-05-18       Impact factor: 10.121

View more
  7 in total

1.  The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function.

Authors:  Saeko Kumon; Takahito Moriyama; Takahiro Kamiyama; Kazunori Karasawa; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2019-12-16       Impact factor: 2.801

2.  Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan.

Authors:  Takahito Moriyama; Hiroshi Kataoka; Kosaku Nitta; Keita Hirano; Keiichi Matsuzaki; Takashi Yasuda; Yoshinari Yasuda; Kentaro Koike; Shoichi Maruyama; Takashi Yokoo; Seiichi Matsuo; Tetsuya Kawamura; Yusuke Suzuki
Journal:  Clin Exp Nephrol       Date:  2020-09-03       Impact factor: 2.801

Review 3.  Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis.

Authors:  Jiayu Duan; Dongwei Liu; Guangcai Duan; Zhangzuo Liu
Journal:  Int Urol Nephrol       Date:  2016-10-08       Impact factor: 2.370

4.  Long-Term Beneficial Effects of Tonsillectomy on Patients with Immunoglobulin A Nephropathy.

Authors:  Takahito Moriyama; Kazunori Karasawa; Yoei Miyabe; Kenichi Akiyama; Yuko Iwabuchi; Shota Ogura; Tomo Takabe; Naoko Sugiura; Momoko Seki; Norio Hanafusa; Keiko Uchida; Kosaku Nitta
Journal:  Kidney360       Date:  2020-09-02

5.  Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification.

Authors:  Keita Hirano; Hoichi Amano; Tetsuya Kawamura; Kyoko Watanabe; Kentaro Koike; Akihiro Shimizu; Satoshi Endo; Nobuo Tsuboi; Hideo Okonogi; Yoichi Miyazaki; Masato Ikeda; Kazushige Hanaoka; Makoto Ogura; Satoru Komatsumoto; Takashi Yokoo
Journal:  Clin Exp Nephrol       Date:  2015-09-28       Impact factor: 2.801

6.  Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy.

Authors:  Ritsuko Katafuchi; Tetsuya Kawamura; Kensuke Joh; Akinori Hashiguchi; Satoshi Hisano; Akira Shimizu; Yoichi Miyazaki; Masaharu Nagata; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2015-09-09       Impact factor: 2.801

7.  A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy.

Authors:  Yoshia Miyawaki; Takayuki Katsuyama; Ken-Ei Sada; Sumie Hiramatsu; Keiji Ohashi; Michiko Morishita; Eri Katsuyama; Haruki Watanabe; Mariko Takano-Narazaki; Noriko Toyota-Tatebe; Katsue Sunahori-Watanabe; Tomoko Kawabata; Tatsuyuki Inoue; Masaru Kinomura; Hitoshi Sugiyama; Jun Wada
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.